Name: 📋 Supported Conditions
Author: Yungho

Skills suchen.../

📋 Supported Conditions | Skills Pool

Category	Systolic	Diastolic	Action
Normal	<120	<80	Maintain healthy lifestyle
Elevated	120-129	<80	Lifestyle modifications
Stage 1	130-139	80-89	Lifestyle + consider medication
Stage 2	≥140	≥90	Medication + lifestyle
Crisis	≥180	≥120	Emergency evaluation

Risk Category	Target BP
Low CV risk (<10%)	<140/90 mmHg
Moderate risk (10-20%)	<130/80 mmHg
High risk (>20%)	<130/80 mmHg
Diabetes + HTN	<130/80 mmHg
CKD + HTN	<130/80 mmHg
Elderly (≥65)	<130/80 mmHg (if tolerated)

Complication	Screening Test	Frequency
Retinopathy	Dilated eye exam	Annually
Nephropathy	UACR + eGFR	Annually
Neuropathy	Monofilament test	Annually
CVD	BP, lipids, ECG	Each visit / Annually
Foot ulcers	Comprehensive foot exam	Annually (high risk: quarterly)

TI-RADS Level	Points	Malignancy Risk	Management
TR1	0	<2%	Benign, no FNA
TR2	2	<2%	Not suspicious, no FNA
TR3	3	~5%	Follow-up if ≥2.5cm, FNA if ≥2.5cm
TR4	4-6	5-20%	Follow-up if ≥1.5cm, FNA if ≥1cm
TR5	≥7	>20%	Follow-up if ≥1cm, FNA if ≥1cm

Feature	0 Points	1 Point	2 Points	3 Points
Composition	Cystic	Spongiform	Mixed	Solid
Echogenicity	Anechoic	Hyperechoic	Isoechoic	Hypoechoic
Shape	-	-	Wider-than-tall	Taller-than-wide
Margin	Smooth	-	Ill-defined	Extrathyroidal
Echogenic Foci	None	Large	Punctate	-

TI-RADS	Size	Initial Follow-up	Ongoing
TR3	<2.5cm	1 year	Every 1-2 years if stable
TR3	≥2.5cm	Consider FNA	-
TR4	<1.5cm	1 year	Every 1-2 years if stable
TR4	≥1.5cm	Consider FNA	-
TR5	<1cm	1 year	Annual for up to 5 years
TR5	≥1cm	FNA recommended	-

BI-RADS	Malignancy Risk	Management
0	Incomplete	Additional imaging needed
1	0%	Negative, routine screening
2	0%	Benign, routine screening
3	<2%	Probably benign, 6-month follow-up
4A	2-10%	Low suspicion, biopsy consideration
4B	10-50%	Moderate suspicion, biopsy recommended
4C	50-95%	High suspicion, biopsy strongly recommended
5	>95%	Highly suggestive of malignancy
6	100%	Known biopsy-proven malignancy

Nodule Size	Low Risk Patient	High Risk Patient
<6mm	No routine follow-up	Optional CT at 12 months
6-8mm	CT at 6-12 months	CT at 6-12 months, then 18-24 months
>8mm	Consider 3-month CT, PET, or biopsy	Consider 3-month CT, PET, or biopsy

Category	Name	WBC in EPS	Culture
I	Acute Bacterial	Positive	Positive
II	Chronic Bacterial	Positive	Positive
IIIA	Inflammatory CPPS	Positive	Negative
IIIB	Non-inflammatory CPPS	Negative	Negative
IV	Asymptomatic	Positive	Negative

Factor	Correlation	Recommendation
Sodium intake	r = 0.6-0.7 (positive)	Reduce to <2300 mg/day
Exercise frequency	r = -0.5 to -0.7 (negative)	150 min/week moderate
Sleep quality	r = -0.6 to -0.7 (negative)	Prioritize 7-8 hours
Stress level	r = 0.4-0.6 (positive)	Daily meditation 10 min
Alcohol intake	r = 0.4-0.5 (positive)	Limit to ≤2 drinks/day
Potassium intake	r = -0.4 to -0.5 (negative)	Increase potassium-rich foods

Factor	Correlation	Recommendation
Carb intake	r = 0.6-0.7 (positive)	Control refined carbs
Post-meal exercise	r = -0.5 to -0.6 (negative)	15-30 min walk after meals
Medication adherence	r = 0.7-0.8 (positive)	Set reminders, pill organizer
Fiber intake	r = -0.4 to -0.5 (negative)	25-30g fiber/day
Sleep duration	r = -0.4 to -0.5 (negative)	7-8 hours sleep
Stress level	r = 0.5-0.6 (positive)	Stress management techniques

Factor	Correlation	Recommendation
Iodine intake	U-shaped	150 mcg/day (not too little, not too much)
TSH level	r = 0.5 (positive)	Monitor TSH every 6-12 months
Cancer anxiety	r = 0.6 (positive)	Reassurance: TR3 <5% risk

# [Condition] Management Report

**Date**: YYYY-MM-DD
**Condition**: [Hypertension / Diabetes / Thyroid Nodule / etc.]

---

## 🚨 Risk Assessment

**Current Status**: [Controlled / Needs Attention / Urgent]
**Risk Level**: 🟢 Low / 🟡 Medium / 🔴 High

**Key Concerns**:
- [Concern 1]
- [Concern 2]

---

## 📈 Current Metrics

| Parameter | Current | Target | Status |
|-----------|---------|--------|--------|
| [Parameter 1] | [Value] | [Target] | ✅/⚠️/❌ |
| [Parameter 2] | [Value] | [Target] | ✅/⚠️/❌ |

---

## 🔗 Correlation Insights

### [Factor A] ↔ [Condition]
**Correlation**: r = [value] ([Strength])
**What this means**: [Interpretation]
**Action**: [Specific recommendation]

---

## 📋 Action Plan

### Today
- [ ] [Action 1]
- [ ] [Action 2]

### This Week
- [ ] [Action 3]
- [ ] [Action 4]

### This Month
- [ ] [Follow-up test/appointment]
- [ ] [Goal]

---

## 📅 Follow-Up Schedule

| Test/Visit | Due Date | Status |
|------------|----------|--------|
| [Test 1] | YYYY-MM-DD | Due/Completed |
| [Test 2] | YYYY-MM-DD | Due/Completed |

---

## ⚠️ When to Seek Immediate Care

- [Red flag symptom 1]
- [Red flag symptom 2]
- [Red flag symptom 3]

---

## 📚 Patient Education

[Condition-specific education points]

---

**Disclaimer**: This analysis is based on your provided health data and is for informational purposes only. It does not replace professional medical diagnosis or treatment. Always consult your healthcare provider for medical concerns.

Skill	Relationship
musculoskeletal-care	Osteoporosis bone density management, fracture risk assessment
fitness-coach	Exercise prescription for chronic conditions
medication-manager	Medication adherence tracking
nutrition-advisor	DASH diet, diabetic diet, calcium/Vitamin D
vital-monitor	BP, glucose trend tracking
preventive-care	Screening schedules

Population	Fasting BG	Post-Meal BG	HbA1c
Most adults	80-130 mg/dL	<180 mg/dL	<7.0%
Pregnancy	<95 mg/dL	<140 mg/dL	<6.5%
Elderly/frail	90-150 mg/dL	<200 mg/dL	<8.0%
High hypo risk	100-180 mg/dL	<200 mg/dL	<7.5%

Range	Target	Clinical Significance
70-180 mg/dL	>70%	Time in target range
<70 mg/dL	<4%	Hypoglycemia
<54 mg/dL	<1%	Severe hypoglycemia
>180 mg/dL	<25%	Hyperglycemia
>250 mg/dL	<5%	Severe hyperglycemia

Age	Primary Modality	Additional
<30	Ultrasound	MRI if high risk
30-39	Ultrasound + Mammogram	-
≥40	Mammogram + Ultrasound	MRI if dense breasts

BI-RADS	Follow-up	Duration
1-2	Routine screening	Annual (age ≥40)
3	6, 12, 24 months	If stable at 2 years → routine
4A-C	Biopsy	Within 2-4 weeks
5	Biopsy + Oncology	Immediate

Type	Size	Management
Pure GGN	<6mm	No routine follow-up
Pure GGN	≥6mm	CT at 6-12 months, then every 2 years until 5 years
Part-solid	≥6mm	CT at 3-6 months, then annual for 5 years

Parameter	Frequency	Target
Home BP	2x/day (morning/evening)	<130/80 mmHg
Weight	Weekly	Stable
Sodium intake	Daily log	<2300 mg/day
Exercise	Weekly log	150 min/week moderate
Medication adherence	Daily	>90%

Parameter	Frequency
NIH-CPSI score	Every 4-6 weeks
Urinalysis	Every 3 months
PSA (if age ≥50)	Annually
Post-void residual	If voiding symptoms worsen

Type	Timing	Common Triggers
Seasonal	Spring/Fall	Tree pollen, grass, ragweed
Perennial	Year-round	Dust mites, pet dander, mold
Occupational	Work days	Chemicals, dust, latex

Severity	Sleep	Daily Activities	Symptoms
Mild	Normal	Normal	Bother some
Moderate-Severe	Disturbed	Impaired	Troublesome

Factor	Correlation	Recommendation
Cycle phase	Cyclical	Track timing; many are fibrocystic changes
Caffeine	r = 0.3 (positive)	Consider reduction if symptomatic

Factor	Correlation	Recommendation
Smoking history	r = 0.6-0.8 (positive)	Critical: Smoking cessation
Nodule growth	Variable	Follow Fleischner guidelines

📋 Supported Conditions

📋 Supported Conditions

Cardiometabolic Conditions

Nodule Management (NEW)

Urological Conditions

📋 Supported Conditions

📋 Supported Conditions

Cardiometabolic Conditions

Nodule Management (NEW)

Urological Conditions

Allergic Conditions

🫀 Hypertension Management

BP Classification (ACC/AHA 2017)

Target BP by Risk Profile

Monitoring Schedule

Lifestyle Recommendations

🩸 Diabetes Management

Glucose Targets (ADA Standards)

Time-in-Range (CGM Metrics)

Complication Screening Schedule

Sick Day Management

🦋 Thyroid Nodule Management

TI-RADS Classification (ACR 2017)

Ultrasound Features (Point System)

Follow-Up Schedule

Growth Definition

Patient Education

🎗️ Breast Nodule Management

BI-RADS Classification (ACR)

Imaging Modality by Age

Follow-Up Schedule

Cyclical Breast Changes

Patient Education

🫁 Lung Nodule Management

Fleischner Society Guidelines (2017)

Solid Nodules

Subsolid Nodules

Risk Stratification

Growth Assessment

Smoking Cessation (Critical)

Patient Education

🚹 Chronic Prostatitis Management

NIH-CPSI Scoring System

Classification (NIH)

Treatment Approach by Category

Lifestyle Recommendations

Monitoring Schedule

When to Refer to Urology

🤧 Allergy Management

Allergic Rhinitis Classification

ARIA Classification

Stepwise Treatment (ARIA Guidelines)

Preemptive Treatment

Trigger Avoidance

Food Allergy Management

🔗 Cross-Domain Correlation Analysis

Hypertension Correlations

Diabetes Correlations

Nodule-Specific Correlations

📊 Output Format

🛡️ Safety Boundaries

✅ Can Do

❌ Cannot Do

🚨 Emergency Triggers

🔗 Cross-References

📚 References

Clinical Guidelines

Risk Calculators

Hr Pro

Mental Health Analyzer

Satori

Claude Ally Health

Wellally Tech

Tcm Constitution Analyzer